法律意见书 广东华商律师事务所 本法律意见书仅对本次会议召集和召开的程序、出席本次会议的人员资格、 召集人资格及表决程序是否符合相关法律、法规和《公司章程》的规定以及本次 会议审议议案的表决结果是否有效进行核查并发表意见，并不对本次会议所审议 的议案内容以及该等议案所涉及的事实或数据的真实性和准确性发表意见。 本所律师同意将本法律意见书作为公司本次会议的必备文件予以公告，并依 法对本所出具的法律意见书承担责任。 本所律师根据有关法律法规的要求，按照律师行业公认的业务标准、道德规 范和勤勉尽责精神，对与出具本法律意见书有关的文件和以下事实进行了核查和 现场见证，现就本次会议涉及的相关法律事项出具法律意见如下： 关于深圳市尚荣医疗股份有限公司 2023年年度股东大会的 法律意见书 二○二四年五月十四日 1 法律意见书 致：深圳市尚荣医疗股份有限公司 广东华商律师事务所（以下简称"本所"）接受深圳市尚荣医疗股份有限公 司（以下简称"公司"）的委托，指派本所周玉梅律师、李世琦律师（以下简称 "本所律师"）出席公司2023年年度股东大会（以下简称"本次会议"）。本所 律师依据《中华人民共和国证券法》（以下简称《证券法》 ...

深圳市尚荣医疗股份有限公司 | 证券代码：002551 | 证券简称：尚荣医疗 | 公告编号：2024-046 | | --- | --- | --- | | 债券代码：128053 | 债券简称：尚荣转债 | | 2023 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 2、本次股东大会不涉及变更以往股东大会已通过的决议。 3、为保护中小投资者利益，本次股东大会采用中小投资者单独计票。中小 投资者为公司董监高人员以外及单独或者合计持有本公司股份低于 5%（不含） 股份的股东。 一、会议召开及出席情况 （一）会议召开情况 1、会议召集人：公司董事会。 2、会议时间： （1）现场会议召开时间：2024年5月14日（星期二）下午14:30； （2）网络投票时间：2024年5月14日 其中，通过深圳证券交易所交易系统进行网络投票的时间为2024年5月14日 的交易时间即：9:15—9:25，9:30—11:30和13:00—15:00；通过深圳证券交易所 互联网投票系统投票的时间为2024年5月14日上午9:15至下午15:00 ...

| 证券代码：002551 | 证券简称：尚荣医疗 | 公告编号：2024-045 | | --- | --- | --- | | 债券代码：128053 | 债券简称：尚荣转债 | | 深圳市尚荣医疗股份有限公司 关于首次回购公司股份的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 三、其他说明 公司首次回购股份的时间、数量、价格及集中竞价交易的委托时段均符合《深 圳证券交易所上市公司自律监管指引第9号——回购股份》第十七条、十八条的 相关规定。 （一）公司未在下列期间内回购公司股票： 1、自可能对本公司股票交易价格产生重大影响的重大事项发生之日或者在 决策过程中，至依法披露之日内； 2、中国证监会及深圳证券交易所规定的其他情形。 （二）公司未违反下列进行回购股份的要求： 一、回购股份事项概述 深圳市尚荣医疗股份有限公司(以下简称"公司"或"本公司")于 2024年 3月9日，公司召开的第七届董事会第十八次临时会议，审议通过了《关于回购公 司股份方案的议案》，同意公司拟使用自筹资金以集中竞价交易方式回购公司股 份，本次回购股份将用于维护公司价值及股东权 ...

| 证券代码：002551 | 证券简称：尚荣医疗 | 公告编号：2024-044 | | --- | --- | --- | | 债券代码：128053 | 债券简称：尚荣转债 | | 深圳市尚荣医疗股份有限公司 关于回购股份进展情况的公告 截至2024年4月30日，公司尚未实施股份回购。 三、其他说明 公司后续将严格按照《上市公司股份回购规则》、《深圳证券交易所上市公司 自律监管指引第9 号——回购股份》等相关规定，在回购期限内依据本次回购公 司股份方案实施回购计划，同时根据回购股份事项进展情况及时履行信息披露义 务，敬请广大投资者注意投资风险。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、回购股份事项概述 深圳市尚荣医疗股份有限公司(以下简称"公司"或"本公司")于 2024年 3月9日，公司召开的第七届董事会第十八次临时会议，审议通过了《关于回购公 司股份方案的议案》，同意公司拟使用自筹资金以集中竞价交易方式回购公司股 份，本次回购股份将用于维护公司价值及股东权益。本次回购数量区间为上限不 超过2,000,000股（占公司总股本的比例不超过0. ...

Financial Performance - The company's operating revenue for Q1 2024 was ¥276,144,984.63, a decrease of 10.75% compared to ¥309,400,196.89 in the same period last year[3] - Net profit attributable to shareholders increased by 97.44% to ¥13,883,489.34 from ¥7,031,710.72 year-on-year[3] - Basic earnings per share doubled to ¥0.02 from ¥0.01, reflecting a 100% increase[3] - Net profit for the current period is ¥18,356,313.59, up 136.5% from ¥7,761,054.60 in the previous period[33] - The company recorded a total profit of ¥22,290,097.70, compared to ¥8,273,742.76 in the previous period, marking a significant increase[33] Cash Flow and Assets - The net cash flow from operating activities improved significantly, reaching ¥54,991,837.20, a 282.82% increase from -¥30,079,313.39 in the previous year[3] - Cash and cash equivalents at the end of the period reached ¥563,864,314.81, an increase from ¥430,492,901.99 in the previous period[35] - The company's cash and cash equivalents increased to CNY 616,750,849.52 from CNY 490,318,652.86, representing a growth of approximately 25.8%[29] - The total assets at the end of the reporting period were ¥3,903,427,764.12, a slight decrease of 0.72% from ¥3,931,719,261.37 at the end of the previous year[3] Liabilities and Equity - The total current liabilities decreased to CNY 785,385,629.60 from CNY 829,793,840.92, a reduction of about 5.3%[31] - The company's total equity increased to CNY 2,765,608,865.10 from CNY 2,747,755,815.63, reflecting a growth of approximately 0.65%[31] - The total liabilities decreased to CNY 1,137,818,899.02 from CNY 1,183,963,445.74, a decline of about 3.9%[31] Investment and Income - The company reported a significant increase in investment income of 2620.27%, amounting to ¥1,567,119.37 due to higher returns from financial products[9] - Investment activities generated a net cash flow of ¥75,627,183.78, an increase from ¥64,062,883.84 in the previous period[35] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 69,326, with the largest shareholder holding 29.54% of the shares[10] - The company plans to repurchase shares with a total amount not exceeding 85.8 million yuan, with a maximum of 2 million shares to be repurchased[24] - The repurchase price is set at no more than 4.29 yuan per share, representing up to 0.24% of the total share capital[24] Project Updates - The company reported a significant order backlog with major contracts totaling ¥15,000 million for the Henan Province Ningling County People's Hospital project and ¥60,000 million for the Shaanxi Province Chengcheng County Hospital project, both of which are in the completion phase[14] - The company has ongoing projects including the Guangdong Province Heshan City People's Hospital construction with a contract value of ¥37,611.19 million, currently in the final stages of construction[14] Restructuring and Impairment - The company is actively monitoring the restructuring of Xuchang Second People's Hospital, with a final arbitration ruling made on December 31, 2021, regarding outstanding payments owed to the company[18] - The total declared debt for the restructuring of the Xuchang Second People's Hospital is estimated at 3.5 billion yuan, with principal debt around 2.9 billion yuan[22] - The company has recognized a credit impairment loss of 177.22 million yuan based on the recoverable value of its debts to the Xuchang Second People's Hospital[22] Other Financial Metrics - The company recorded a 667.29% increase in income tax expenses, amounting to ¥3,421,095.95, due to a rise in total profit[9] - The company's long-term equity investments remained relatively stable at CNY 95,251,585.15, down slightly from CNY 95,565,836.50[29] - The remaining balance of convertible bonds as of March 31, 2024, was CNY 189,564,900, with a total of 8,809 shares converted during the reporting period[26] Audit Status - The company has not undergone an audit for the first quarter report[37]

深圳市尚荣医疗股份有限公司 关于公司2023年度会计师事务所履职情况的评估报告 深圳市尚荣医疗股份有限公司(以下简称"公司"或"本公司")聘请亚太 （集团）会计师事务所（特殊普通合伙）（以下简称"亚太会计师事务所"）为公 司2023年度审计机构。根据财政部、国务院国有资产监督管理委员会、中国证券 监督管理委员会颁布的《国有企业、上市公司选聘会计师事务所管理办法》，公 司对亚太会计师事务所在2023年度审计工作的履职情况进行了评估，具体情况如 下： 一、2023 年年审会计师事务所基本情况 1、基本信息 会计师事务所名称：亚太（集团）会计师事务所（特殊普通合伙） 成立日期：2013 年 9 月 2 日 2、投资者保护能力 亚太会计师事务所已计提职业风险金3,499.36万元，购买职业保险累计赔偿 限额人民币8,439.79万元。职业风险基金计提和职业保险购买符合财会【2015】 13号等规定。近三年（最近三个完整自然年度及当年）在执业行为相关民事诉讼 中承担民事责任的情况如下： 组织形式：特殊普通合伙 注册地址：北京市丰台区丽泽路 16 号院 3 号楼 20 层 2001 首席合伙人：邹泉水 业务资质：拥有会计 ...

关于深圳市尚荣医疗股份有限公司 募集资金年度存放与实际使用情况的 鉴证报告 亚会专审字(2024)第 01610007 号 亚太(集团) 特殊普通合伙) H 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.cn）"进行查询 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http:///ac.mof.gov.cn）"进行查询 ： 报告编码： 目 录 : 11 T太(集团)会计师事务所(特殊普通合伙) sia Pacific (Group) CPAs(Special General Partnership) 地址:北京市丰台区丽泽路 16 号 院 3 号楼 20 层 2001 邮编:100073 电话/传真:010-88312386 关于深圳市尚荣医疗股份有限公司 募集资金年度存放与实际使用情况的鉴证报告 亚会专审字(2024)第 01610007 号 深圳市尚荣医疗股份有限公司全体股东: 我们接受委托,对后附的深圳市尚荣医疗股份有限公司(以下简称"尚荣医疗 公司")截至2023年12月31日止的《关于2023年度募集资金存放与使用情况的 专项报告》进行了 ...

证券代码：002551 证券简称：尚荣医疗 公告编号：2024-032 债券代码：128053 债券简称：尚荣转债 深圳市尚荣医疗股份有限公司 第七届监事会第六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市尚荣医疗股份有限公司（以下或简称"公司"）第七届监事会第六次 会议，于2024年4月10日以书面、传真及电子邮件的方式发出会议通知和会议议 案，并于2024年4月20日在公司会议室以现场方式召开，本次会议应到监事3名， 实到监事3名，会议由监事会主席黄雪莹女士主持，会议的召集和召开符合《中 华人民共和国公司法》及《公司章程》的规定。经与会监事认真审议，形成如下 决议： 一、审议通过了《公司2023年度监事会工作报告》 表决结果：3票赞成，0票反对，0票弃权。 监事会同意将本议案提交公司2023年年度股东大会审议。 具 体 内 容 详 见 同 日 在 公 司 指 定 信 息 披 露 网 站 巨 潮 资 讯 网 （www.cninfo.com.cn）上披露的《深圳市尚荣医疗股份有限公司2023年度财务 决算报告》。 三、审议通过了《公司2 ...

深圳市尚荣医疗股份有限公司 董事会关于会计政策变更追溯调整财务报表数据的专项说明 一、本次追溯调整的概述 深圳市尚荣医疗股份有限公司(以下简称"公司"或"本公司") 于2023年 4月29日披露了《关于会计政策变更的公告》（公告编号：2023-029），公司自2023 年1月1日起执行财政部颁布的《企业会计准则解释第16号》"关于单项交易产生 的资产和负债相关的递延所得税不适用初始确认豁免的会计处理"的规定。 2024年4月20日召开第七届董事会第六次会议、第七届监事会第六次会议， 审议通过了《关于会计政策变更追溯调整财务报表数据的议案》。公司按照《企 业会计准则解释第16号》中"关于单项交易产生的资产和负债相关的递延所得税 不适用初始确认豁免的会计处理"的相关规定，对2022年度财务报表相关项目进 行追溯调整。本次追溯调整已经亚太（集团）会计师事务所（特殊普通合伙）审 计，详见公司2023年年度审计报告附注四.33-重要会计政策、会计估计的变更。 2022 年度 | 报表项目 | | 年 2022 12 31 | 月 | 日 | | | --- | --- | --- | --- | --- | --- | ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion yuan in 2023, representing a year-on-year growth of 15%[1]. - The company's operating revenue for 2023 was ¥1,192,887,048.61, a decrease of 6.49% compared to ¥1,275,709,968.34 in 2022[25]. - The net profit attributable to shareholders for 2023 was -¥148,889,156.24, showing an improvement of 51.67% from -¥308,062,987.97 in 2022[25]. - The cash flow from operating activities was ¥17,633,369.87, a significant decline of 81.72% compared to ¥96,453,250.16 in 2022[25]. - The total assets at the end of 2023 were ¥3,931,719,261.37, representing a decrease of 7.71% from ¥4,260,470,294.03 at the end of 2022[25]. - The basic earnings per share for 2023 was -¥0.1762, an improvement of 51.69% from -¥0.3647 in 2022[25]. - The company reported a quarterly revenue of ¥274,089,386.32 in Q4 2023, with a net profit of -¥162,404,237.58 for the same quarter[33]. - The company’s net assets attributable to shareholders decreased by 5.18% to ¥2,614,169,214.73 at the end of 2023 from ¥2,757,098,024.46 at the end of 2022[25]. - The company’s diluted earnings per share for 2023 was -¥0.1685, reflecting a 51.66% improvement from -¥0.3486 in 2022[25]. - The company achieved operating revenue of CNY 1,192.89 million in 2023, a year-on-year decrease of 6.49%[71]. Market Expansion and Strategy - User data indicates that the company served over 500 hospitals, with a 20% increase in new client acquisitions compared to the previous year[1]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share within the next two years[1]. - The company has set a revenue guidance of 1.5 billion yuan for 2024, projecting a growth rate of 25%[1]. - The company aims to enhance its R&D capabilities in high-end medical devices, including laparoscopic surgical robots and biodegradable vascular stents[45]. - The company is positioned to benefit from the "14th Five-Year Plan" which emphasizes the expansion of quality medical resources and the reform of public hospitals[42]. - The company aims to expand both domestic and international markets, enhancing its global marketing network[124]. Research and Development - The company has invested 100 million yuan in R&D for innovative healthcare solutions, aiming to improve operational efficiency and patient outcomes[1]. - Research and development investments increased by 30%, totaling 150 million RMB, focusing on advanced medical technologies[161]. - The company is currently developing several new technologies and products, including an enhanced sensitivity SPR biosensor and a digital integrated operating room[85]. - The company holds over 100 patents, contributing to its continuous development and innovation[69]. Partnerships and Acquisitions - A strategic acquisition of a local medical technology firm is anticipated to enhance the company's product offerings and is expected to close by Q3 2024[1]. - The company completed a strategic acquisition of a local competitor for 300 million RMB, enhancing its product portfolio[161]. - The company has established a new partnership with a leading healthcare provider, which is expected to generate an additional 150 million yuan in annual revenue[1]. Financial Management and Governance - The company will not distribute cash dividends for the fiscal year, opting to reinvest profits into growth initiatives[1]. - The company has established a strict management system for the raised funds to ensure safety and efficiency in usage[106]. - The company has implemented a robust employee performance evaluation and incentive mechanism to foster a fair and efficient work environment[138]. - The company is committed to continuous improvement in corporate governance and compliance with relevant laws and regulations[135]. - The company received a rectification order from the Shenzhen Securities Regulatory Bureau on November 27, 2023, requiring it to correct identified issues[139]. Operational Efficiency - The gross margin improved to 35%, up from 30% in the previous year, reflecting better cost management and pricing strategies[1]. - The company plans to implement cost-cutting measures, targeting a reduction of 5% in operational expenses over the next year[161]. - The company has established a comprehensive sales and service network across major provinces, enhancing its market presence[68]. Industry Trends and Insights - The total healthcare expenditure in China reached approximately ¥84,846.7 billion in 2022, reflecting a year-on-year growth of 12.2%[39]. - The medical device market in China reached approximately CNY 1.3 trillion in 2022, with a year-on-year growth of 12%, outpacing the global market growth rate by three times, capturing over one-third of the global market share[54]. - The Chinese medical device industry is expected to continue its growth trajectory, supported by government policies and increasing healthcare demands[47]. Employee and Management Structure - The total number of employees at the end of the reporting period was 1,345, including 96 from the parent company and 1,259 from major subsidiaries[184]. - The company has a structured training plan aimed at developing a high-quality talent pool and improving market competitiveness[187]. - The management team has undergone training and stock incentive programs to align interests and enhance stability[69]. Compliance and Risk Management - The company has established a robust internal supervision mechanism, including a supervisory board and an audit committee to oversee the effectiveness of internal controls[192]. - The internal control audit report confirmed the effectiveness of the internal control over financial reporting as of December 31, 2023[195]. - The company has not reported any risks during the supervisory activities of the supervisory board[183].